a key decision in may about whether or not they'll approve this drug from novartis. >> talking about how some of these have very small addressable markets. that's true for this one one is a relatively rare muscle disease and another disease, basically has really a handful of patients born every year. with the disease in the united states maybe five or ten. so this really, very much personalized medicine. you may have rare and serious diseases. >> fewer than 100 babies born in the u.s. with this rare condition here regenex and bio. up 20% over the past month is it so widely viewed that these are candidates with a built-in premium >> yes, not as cheap as they once were. etf gene therapy they make the vector which are the delivery mechanism to get the healthy genes that need them basically part of 20 or 30 other companies able to get royalties on commercial success of some of the drugs with nonovartis. it's about a $2 billion market value, not small but not huge right now. given what big pharma companies are paying right now for companies. >> sarepta. >> muscular dystrophy. there's real

novartis will be presenting data -- american academy of n eurology coming up in may.ting data on another of the companies growth drivers, and i think people will be looking at that. david: so if the price has to do with what an investor might want to pay on the stock, what about if another company wants to take a look at that and say, that is attractive? they might try to buy the company? >> it is possible, but i am not sure that this type of megamerger is really involved right now. the analog people might point to is the bristol deal, but look at opposition. bristol shareholders speaking up saying, we don't want you to buy a deal that is oriented around cash flow but still implies a long-term growth overhang. for biogen, yes, there are some promising high assets that probably aren't really priced into the stock. but ultimately if you are in buyer it looks more financially deal.ed as a and if you can't get a conviction on some of these pipeline projects, i just am not sure. given the opposition with bristol shareholders, i don't think there will be support for a megam

did you collect $1.2 million or so from novartis? mr. cohen: i did. >> for access to the trump administration? mr. cohen: no sir. >> why did you collect? mr. cohen: because they came to be based upon my knowledge of the enigma donald trump, what he thinks. please let me finish. >> did they pay you $1.2 million to give them advice? mr. cohen: yes they did. a multibillion dollar conglomerate came to me looking for information, not something that is unusual here in d.c. looking for information and they believe i had a value. and that was the insight i was capable of offering them. and they were willing to pay. >> how many times do meet with them? for $1.2 million how many times did you meet with them? mr. cohen: i provided them with both in person as well as telephone access whenever they needed. i don't recall sir. >> did you ever talk to them? mr. cohen: on several occasions yes. >> how many? mr. cohen: six times. >> six times, wow. $200,000 a call. mr. cohen: i also would like to bring to your -- >> did you get money from the bank --? mr

novartis is coming out with a gene therapy drug very soon.-- roche is also working on a competitive drug for that. they're very strong on multiple sclerosis, or that is kind of a mature market. people are asking what they are going to do now. are they going to have to look to m&a? this was one of the big things in their future. not only did it not work, it had so little efficacy, and they stopped it a full year early. : interesting and certainly disappointing. thank you so much for your reporting today. coming up, apple has been on a hardware spree this week and analysts are taking notice. what analysts are expecting to go into the iphone maker's upcoming streaming event next. this is bloomberg. ♪ emily: apple has announced four new products this week including new ipads, imacs, and airpods. the stock has gained in the last -- in nine of the last 10 trading days. what is making analysts so optimistic? >> i think it is this new reinvention that apple is trying . it used to be a hardware company . for more than four decades, it has mostly been

novartis will hit with a therapy druchlth maybe this ye drug, maybe this year. so this could get -- this could be a serious problem for biogen going forward and they spent about $12 billion in the last four years buying back stock now there is a new question of the pipeline of drugs coming in. >> who else has promising research in this area for people looking at what may treat or cure alls hezheimer's. >> it's scant. treating long-term care liabilities is everyone's problem, whether or not you know someone with this disease. i think any promising alzheimers treatments are years away. we have to reset the clock again, that's a bummer. >> you said here, there are a few other companies where maybe investors should look to, acadia, neurocriminal sage which had a treatment yesterday for post-partum depression >> sure, biogen has been focused on central nervous system disorders. none of these have a lead. but at the same time, they relationship within biogen's strategy it will be a natural tuck in acquisition. at the same time, biogen may need to rethink whether the c

he looked at consulting contracts michael cohen entered into including with novartis, at&t, the parentd a consulting contract with was columbus nova, a u.s. investment firm with ties to a russian oligarch, one of the wealthiest men in russia. he's someone who the fbi stopped when his plane landed in the u.s. to question him. that was part of mueller's investigation. all of that carried with it and became known as summer when michael cohen's banking records became public. we learned he had all these consulting contracts. that was something that the special counsel's office had also investigated to see what the connections were. there was nothing ever charged related to the relationships or anything illegal about the relationships. but it was part of the effort by michael cohen once he did not go to washington with trump when he became president that he started to look for these consulting contracts with various companies. essentially selling his access to the president and his knowledge of the president. pop poppy? >> thank you. we'll let you get back to it. paul, let's talk about the s

. >> should we be thinking about brammer when new ipos come out or when glaxo buys or novartis becausey're all doing it >> yeah. so the customer base will be both large cap and the emerging companies and that's one of the great things about thermo fisher scientific is we serve the whole range of the industry and help the young companies get started and we also help the large companies as they shift towards new modalities of medicine. >> i think it's important to point out that there are some companies that china can't do without. when i see your numbers in china i just imagine the hospitals with 500,000 people each one and that's a fabulous growth business for you and one of the key elements have been our strength in emerging markets and china the second largest market for the company and 10% of the revenue and last year grew 20% organically. expanding health care for the population, controlling pollution, improving food safety and those are things that we enable for them and it's also important to point out that you're a company of great structures and ethics and there's some business

and what the documents say is that he had been paid by several companies, a swiss company, novartis, another swiss company owned by a russian, a kazakh bank, and also the korean aerospace company. so there were questions about whether he was failing to register as a foreign agent. he was never charged with that. and then through the bank records, according to the court documents, that's when they got onto the whole question about illegal contributions involving hush money payments. now, what we can't tell from the documents is why they started investigating michael cohen in the first place, what was it that got their attention. and we just don't know the answer to that. >> jill wine-banks, what did you take away from what we learned here? there was a lot that was redacted, we know the feds, while they didn't listen in on michael cohen's calls, they did track who those calls were from and who he was reaching out to. >> we learned that tactics used against the mafia were used against michael cohen. pen registers are often used in mafia cases. and as pete just said, we don't know why th

taking a look at the losers, novartis taking the most points away from the stoxx 600, and that you have american and linda on the downside, in terms of the biggest point, nor day a is the downgrade,her on the this is the see -- grocer down on concerns about competition from amazon in the u.s. >> interesting that the daily mail is one of the biggest -- one of the headlines across the bloomberg, we will keep an eye on that in return to the individual movers. european markets opening higher. the u.s. and china are close to a trade teal that could lift most tariffs. bloomberg's understand this could happen if beijing follows through on intellectual property rights. china is also reportedly offering lower tariffs on u.s. foreign goods and cars. let's get up-to-date with the latest news flow. david igo's joins us from beijing. give us the latest. what do we know about the potential for a deal soon on trade? >> right. they mention some of the conditions that need to be in place and a lot of those things are coming together. a good example would be the tariffs on u.s. agricultural they will be

the swiss drug company novartis says the list price for that drug will be $88,000 per year. >>> the "r from more than one million privately owned wells could face the risk of contamination from the recent flooding in the midwest. they are located mostly in rural areas. these wells are not typically regulated by the epa. contaminated water can carry harmful bacteria, raw sewage, pesticides, and spilled fuel. experts say well owners affected by flooding should watch for any change in the color, smell, or taste of their water. they're encouraged to consider alternatives such as bottled water. >>> the family of a man who died in a georgia jail is filing a lawsuit and calling on the justice department to investigate what they say is a troubling pattern of misconduct. 22-year-old shali tilson died of dehydration at the da county jai in the same jail less than three months later. an attorney for both families claims deputies at the jail were negligent and says the county sheriff does not have control over the deputies, some of whom have been linked to alleged crimes themselves. demarco morga

flavor, form factors and that's progressing well we also announced last year agreement with the novartis and expect to deploy medical products into about half a dozen new countries this year. an then also, authentic brands group. we look to bring cbd products to market under brands such as nine west in the u.s. before year end. >> brendan, you mentioned some of the geographic expansions what is your expectation five years from now on what which will be your biggest marks and gauge the percentage break down you expect that to be. >> that's the most difficult question you can ask when's knowable is there's a global growth opportunity. today we started with 41 countries. i think we'll finish 2019 with about somewhere around 50 countries. next year 60 countries and so there's a global growth trajectory we know about and we can forecast that. there's also a global growth opportunity around hemp derived cbd products 50 countries legalized that and we can map that out including the united states. deploy capital and invest accordingly. what is unknown and the big unknown is sort of a third oppor